Global biotherapeutics leader CSL Behring announced that Japan’s Ministry of Health, Labor and Welfare approved Afstyla [lonoctocog alfa] for hemophilia A.
AbbVie announced today a global resolution of all intellectual property-related litigation with Amgen over Amgen’s proposed biosimilar adalimumab product.
Israeli medical device company Magenta Medical said it has raised $15 million in funding led by Massachusetts-based Abiomed Inc., a maker of catheter-based heart pumps, and venture capital firm Pitango.
It has long been thought that electronic data collection, also known as EDC, would be a time-saver when it comes to running clinical trials. But that may not be the case, according to a joint study released by Tufts University and Veeva Systems.
The European Commission approved Regeneron Pharmaceuticals’ and Sanofi’s key biologic treatment dupilumab for moderate-to-severe atopic dermatitis, the two companies said.
Novartis’ research head expects an alliance with a University of California chemistry lab to produce drug candidates within three years as the Swiss company accelerates its hunt for new medicines.
Following a failure to determine clear efficacy in its experimental combo ovarian cancer drug, Mateon ended the drug program and cut 60% of its employees.
The U.S. Attorney’s Office in Chicago charged a former Zacks biotech analyst with securities fraud over allegations of insider trading.
Picking Amsterdam, Barcelona or Vienna as the new headquarters of Europe’s drugs regulator after Brexit would be the best option for retaining staff, according to a survey of its workers.
U.S. Republicans fell short yet again in their seven-year drive to repeal Obamacare, in a bitter defeat that raises more questions about their ability to enact President Donald Trump’s agenda.